<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Adv Nutr</journal-id>
<journal-id journal-id-type="iso-abbrev">Adv Nutr</journal-id>
<journal-id journal-id-type="publisher-id">advances</journal-id>
<journal-title-group>
<journal-title>Advances in Nutrition</journal-title>
</journal-title-group>
<issn pub-type="ppub">2161-8313</issn>
<issn pub-type="epub">2156-5376</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30721959</article-id>
<article-id pub-id-type="pmc">6363529</article-id>
<article-id pub-id-type="doi">10.1093/advances/nmy063</article-id>
<article-id pub-id-type="publisher-id">nmy063</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Supplement</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mechanisms of Action of Probiotics</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Plaza-Diaz</surname>
<given-names>Julio</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruiz-Ojeda</surname>
<given-names>Francisco Javier</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gil-Campos</surname>
<given-names>Mercedes</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-7663-0939</contrib-id>
<name>
<surname>Gil</surname>
<given-names>Angel</given-names>
</name>
<!--<email>agil@ugr.es</email>-->
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
<xref ref-type="aff" rid="aff4">4</xref>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label>Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, Armilla, Granada, Spain</aff>
<aff id="aff2"><label>2</label>Institute of Nutrition and Food Technology “José Mataix,” Biomedical Research Center, University of Granada, Armilla, Granada, Spain</aff>
<aff id="aff3"><label>3</label>Instituto de Investigación Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de Granada, Granada, Spain</aff>
<aff id="aff4"><label>4</label>CIBEROBN (Physiopathology of Obesity and Nutrition CB12/03/30038), Instituto de Salud Carlos III, Madrid, Spain</aff>
<aff id="aff5"><label>5</label>Pediatric Research and Metabolism Unit, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research, Cordoba, Spain</aff>
<author-notes>
<corresp id="cor1">Address correspondence to AG (e-mail: <email>agil@ugr.es</email>)</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date iso-8601-date="2019-02-05" pub-type="epub">
<day>05</day>
<month>2</month>
<year>2019</year>
</pub-date>
<volume>10</volume>
<issue>Suppl 1</issue>
<fpage>S49</fpage>
<lpage>S66</lpage>
<history>
<date date-type="received">
<day>31</day>
<month>1</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>7</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 American Society for Nutrition.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="oup-standard" xlink:href="https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model">
<license-p>This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (<ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model">https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model</ext-link>)</license-p>
</license>
</permissions>
<self-uri xlink:href="nmy063.pdf"></self-uri>
<abstract>
<title>ABSTRACT</title>
<p>Probiotics are living microorganisms that confer health benefits to the host when administered in adequate amounts; however, dead bacteria and their components can also exhibit probiotic properties. <italic>Bifidobacterium</italic> and strains of lactic acid bacteria are the most widely used bacteria that exhibit probiotic properties and are included in many functional foods and dietary supplements. Probiotics have been shown to prevent and ameliorate the course of digestive disorders such as acute, nosocomial, and antibiotic-associated diarrhea; allergic disorders such as atopic dermatitis (eczema) and allergic rhinitis in infants; and <italic>Clostridium difficile</italic>–associated diarrhea and some inflammatory bowel disorders in adults. In addition, probiotics may be of interest as coadjuvants in the treatment of metabolic disorders, including obesity, metabolic syndrome, nonalcoholic fatty liver disease, and type 2 diabetes. However, the mechanisms of action of probiotics, which are diverse, heterogeneous, and strain specific, have received little attention. Thus, the aim of the present work was to review the main mechanisms of action of probiotics, including colonization and normalization of perturbed intestinal microbial communities in children and adults; competitive exclusion of pathogens and bacteriocin production; modulation of fecal enzymatic activities associated with the metabolization of biliary salts and inactivation of carcinogens and other xenobiotics; production of short-chain and branched-chain fatty acids, which, in turn, have wide effects not only in the intestine but also in peripheral tissues via interactions with short-chain fatty acid receptors, modulating mainly tissue insulin sensitivity; cell adhesion and mucin production; modulation of the immune system, which results mainly in the differentiation of T-regulatory cells and upregulation of anti-inflammatory cytokines and growth factors, i.e., interleukin-10 and transforming growth factor; and interaction with the brain-gut axis by regulation of endocrine and neurologic functions. Further research to elucidate the precise molecular mechanisms of action of probiotics is warranted.</p>
</abstract>
<kwd-group kwd-group-type="keywords">
<kwd>bifidobacteria</kwd>
<kwd>lactic acid bacteria</kwd>
<kwd>lactobacilli</kwd>
<kwd>mechanism of action</kwd>
<kwd>probiotics</kwd>
<kwd>volatile fatty acids</kwd>
<kwd>brain-gut axis</kwd>
<kwd>immune system</kwd>
</kwd-group>
<counts>
<page-count count="18"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>